everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...4849505152535455565758...132133»
  • ||||||||||  Avastin (bevacizumab) / Roche, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Review, Journal, Combination therapy:  Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. (Pubmed Central) -  May 21, 2021   
    The review summarizes the effectiveness and available safety data on octreotide LAR in combination with other therapies in patients with NEN and may provide suggestions to address the therapeutic strategy. Further comparative head-to-head studies are needed to understand which is the best combination treatment for patients with progressive NEN after failure of first-line therapy.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    [VIRTUAL] Novel approaches to T-Cell ALL () -  May 20, 2021 - Abstract #SOHO2021SOHO_98;    
    P1, P2, P2
    The combination was well-tolerated, and 10 of 19 T-ALL patients obtained morphologic CR; six of those were MRD negative (<10–4).27 Independent studies from the Bourquin and Yang labs performed ex vivo drug response profiling in a large panel of primary T-ALL samples, finding a high percentage of pediatric T-ALL cases (30– 44%) are sensitive to the tyrosine kinase inhibitor dasatinib.28,29 Both groups demonstrated the responses were not because of the presence of ABL-class fusions...LCK is an SRC-family kinase.29 Both groups demonstrated T-ALL samples were resistant to other ABL-class inhibitors, such as imatinib, that do not target SRC-family kinases...The anti-CD38 monoclonal antibody daratumumab was found to be highly effective in preclinical models of T-ALL, leading to an ongoing trial combining daratumumab with cytotoxic chemotherapy in R/R T-ALL (NCT03384654).32,33 Preclinical studies using allogeneic and autologous CAR-T-cells targeting CD2, CD5, and CD7 have also shown considerable promise, leading to a number of ongoing clinical trials in R/R T-ALL (NCT04572308, NCT04840875, NCT03081910).34 Conclusion In summary, the outcomes for children and young adults with T-ALL have greatly improved over time; yet, not all patients are cured, and new approaches are needed. Improved understanding of T-ALL biology may lead to more accurate risk stratification, identifying patients who are likely to relapse, in order to treat them with novel precision medicine and immunotherapeutic approaches.
  • ||||||||||  cyclosporine / Generic mfg.
    [VIRTUAL] BKV-Associated Urothelial Carcinoma in Patients After Renal and Extrarenal Carcinoma () -  May 18, 2021 - Abstract #ATC2021ATC_1597;    
    Diagnosis occurs often delayed and at an advanced stage, since BKV problems mostly happen up to two years after renal and only rarely after extrarenal TX; therefore BKV testing usually is not done routinely late after renal and in general rarely done at all after extrarenal TX. Prognosis therefore is poor.
  • ||||||||||  dexamethasone / Generic mfg.
    [VIRTUAL] Covid Infection Among Kidney Transplant Recipients: Management and Outcomes () -  May 18, 2021 - Abstract #ATC2021ATC_1416;    
    Due to their immunocompromised state and often more severe clinical presentation, the majority require hospitalization, with a significant number needing ICU admission and mechanical ventilation. Severe illness led to higher use of dexamethasone, remdesivir and covalescent plasma in those who ultimately died of COVID.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Biomarker, Clinical, Journal, Next-generation sequencing:  A deep analysis using panel-based next-generation sequencing in an Ecuadorian pediatric patient with anaplastic astrocytoma: a case report. (Pubmed Central) -  May 15, 2021   
    Next-generation sequencing allows genomic characterization of rare diseases; for instance, this study unraveled a pathogenic single-nucleotide polymorphism related to Li-Fraumeni syndrome and identified possible new drugs that specifically target the patient's variants. Molecular tools should be implemented in routine clinical practice for early detection and effective preemptive intervention delivery and treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma (Pubmed Central) -  May 15, 2021   
    The use of both the combination of nivolumab + ipilimumab and cabozantinib is restricted to intermediate and high-risk patients...Temsirolimus is only approved for high-risk patients.Sunitinib and pazopanib can also be applied as second-line options - for pazopanib the use is restricted to the event of cytokine failure...Furthermore, the combination of lenvatinib + everolimus and axitinib are approved treatment options in the second-line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented in this publication.
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Rapid determination of tacrolimus and sirolimus in whole human blood by direct coupling of solid-phase microextraction to mass spectrometry via microfluidic open interface. (Pubmed Central) -  May 15, 2021   
    The limits of detection were determined to be 0.3 ng mL for tacrolimus, 0.2 ng mL for sirolimus, 0.3 ng mL for everolimus, and 0.3 ng mL for cyclosporine A. The R values for all analytes were above 0.9992 with linear dynamic range from 1.0 mL to 50.0 ng mL for tacrolimus, sirolimus, and everolimus while from 2.5 ng mL to 500.0 ng mL for cyclosporine A. To further evaluate the performance of the present method, 95 residual whole blood samples of tacrolimus and sirolimus from patients undergoing immunosuppression therapy were used to compare the Bio-SPME-MOI-MS/MS method against a clinically validated reference method based on chemiluminescent microparticle immunoassay, showing acceptable results. Our results demonstrated that Bio-SPME-MOI-MS/MS can be considered as a suitable alternative to existing methods for the determination of immunosuppressive drugs in whole blood providing faster analysis, better selectivity and sensitivity, and a wider dynamic range than current existing approaches.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma. (Pubmed Central) -  May 15, 2021   
    This study provides further support that everolimus is still an important option in mRCC treatment after failure of first-line targeted therapy. However, clinical studies are still needed to further improve its therapeutic efficacy.
  • ||||||||||  fulvestrant / Generic mfg.
    Review, Journal:  Exploring the concepts and practices of advanced breast cancer treatment: a narrative review. (Pubmed Central) -  May 15, 2021   
    For mTNBC patients, we found that THA and endostatin exhibited potential efficacy and was well tolerated in pretreated patients. Our concepts and practices will contribute to the design of relevant clinical research and accumulation of evidence, and cure of MBC is promising.
  • ||||||||||  Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST-LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP () -  May 13, 2021 - Abstract #EHA2021EHA_555;    
    We additionally evaluated rrHL patients enrolled in the placebo-controlled randomized GHSG HDR3i trial comparing conventional DHAP vs. everolimus + DHAP salvage therapy prior planned autologous stem-cell transplantation (ASCT)...Conclusion Our analysis of relapse and treatment patterns after contemporary HL therapy provides a robust benchmark to evaluate novel therapeutic strategies in rrHL. We confirm the curative potential of current rrHL treatments including non-ASCT approaches and roughly 50% of rrHL patients do not experience a consecutive relapse after 2nd-line treatment.
  • ||||||||||  lapatinib / Generic mfg., everolimus / Generic mfg., dasatinib / Generic mfg.
    Clinical, Journal:  Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy. (Pubmed Central) -  May 13, 2021   
    Overall, the Rib/Eve concurrent therapy augmented the in vitro cytotoxic effect, compared to Rib/Eve sequential therapy or single treatments. The high DDI prevalence in subjects enrolled on SWOG clinical trials, including a high prevalence that violate trial exclusion criteria, support the need for improved processes for DDI screening to ensure trial subject safety and trial data accuracy.
  • ||||||||||  sirolimus / Generic mfg.
    Clinical, P2b data, P3 data, Journal:  Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. (Pubmed Central) -  May 13, 2021   
    P2
    In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of rapamycin (mTOR) inhibitor, was observed to increase IFN-induced antiviral gene expression and decrease the incidence of respiratory tract infections (RTIs) in older adults...In the phase 2b trial, patients were randomly assigned to using a validated automated randomisation system to oral RTB101 5 mg, RTB101 10 mg once daily, or placebo in part 1 and RTB101 10 mg once daily, RTB101 10 mg twice daily, RTB101 10 mg plus everolimus once daily, or matching placebo in part 2...Further refinement of clinical trial endpoints and patient populations might be required to identify whether upregulation of IFN responses by mTOR inhibitors consistently decreases the incidence or severity of viral infections in older adults. resTORbio and the National Institute on Aging.